TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02257983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPI-743
Description: EPI-743 (2 capsules 200 mg each) taken at a dose of 400 mg P.O. TID for 9 days with noise exposure for 4 hours on Day 8.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 Placebo capsules P.O. TID for 9 days with noise exposure for 4 hours on Day 8.
Study: NCT02108431

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balloon catheter for suprapubic bladder-drainage
Description: suprapubic tube removal was allowed when the anastomosis was watertight, Day 5

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balloon catheter for transurethral bladder-drainage
Description: transurethral catheter withdrawal was allowed when the anastomosis was watertight, Day 5
Study: NCT02884778

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Detection of pain after nociceptive stimulus
Description: We will evaluate the changes of the NoL index absolute values after different types of stimulations such as intubation and electrical tetanic stimulation of the forearm (applied with the standard muscle relaxation monitor) in a patient under general anesthesia + epidural anesthesia for abdominal surgery
Study: NCT04840043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic sympathic harmonization
Description: Treatments that harmonize at the sympathetic nerves or plexus, e.g., sympathetic trunk stimulation by means of the rib-raise technique or stimulation of the prevertebral ganglia.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham intervention
Description: Different location, size and time of the rib-raise technique or stimulation of the prevertebral ganglia.
Study: NCT03958448

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement of extra short implants
Description: placement of an extra short implant in the posterior edentulous ridge

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: maxillary sinus lift, maxillary sinus elevation, maxillary sinus augmentation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: placement of standard implant
Description: placement of standard implant in the posterior edentulous ridge after maxillary sinus augmentation
Study: NCT03528512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam and fentanyl
Description: Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)
Study: NCT02565979

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: resveratrol
Description: Resveratrol will be given for 6 months, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill, also containing 75 mg will be given with dinner. So in total a dose of 150 mg/day will be given.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A placebo will given for 6 months, twice daily. One pill will be provided with lunch, and the other pill will be provided with dinner.
Study: NCT01477931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion extended release
Description: 300mg once a daily, PO, 8weeks
Study: NCT01902550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol tartrate immediate-release (metoprolol IR)
Description: Metoprolol IR will be administered as single oral dose of 100 mg tablet or capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol tartrate immediate-release (metoprolol IR)
Description: Metoprolol IR will be administered as single oral dose of 100 mg tablet or capsule.
Study: NCT05118659

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sustained natural apophyseal glides
Description: It consists on a sustained apophyseal glides in a postero-anterior direction on C2 with a dose of three series of ten repetitions each

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: SHAM SNAG
Description: Subjects on SNAG group received a simulation of the contact used for the SNAGs, without any vertebral glide, and with an active cervical extension
Study: NCT01902550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54452840
Description: JNJ-54452840 (12 ml solution containing 240 mg JNJ-54452840) will be administered intravenously over 1 minute.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54452840
Description: JNJ-54452840 (12 ml solution containing 240 mg JNJ-54452840) will be administered intravenously over 1 minute.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo (normal saline) to JNJ-54452840 will be administered intravenously over 1 minute on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo (normal saline) to JNJ-54452840 will be administered intravenously over 1 minute on Day 1.
Study: NCT02420873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorvotuzumab Mertansine (IMGN901)
Description: 100 mg/m2 by vein on Day 1 and 8 of a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorvotuzumab Mertansine (IMGN901)
Description: 100 mg/m2 by vein on Day 1 and 8 of a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorvotuzumab Mertansine (IMGN901)
Description: 100 mg/m2 by vein on Day 1 and 8 of a 21-day cycle.
Study: NCT03900871

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetylsalicylic acid
Description: Aspirin (aspirin), also known as acetylsalicylic acid (acetylsalicylic acid), is a salicylic acid drug commonly used as a painkiller, antipyretic and anti-inflammatory drug. There is growing evidence that aspirin has a preventive effect on certain cancers, especially gastrointestinal cancers, and that taking aspirin every day can reduce the risk of colon cancer, and in vitro experiments have also shown that aspirin inhibits the growth of a variety of cancer cells and induces apoptosis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: Aspirin (aspirin), also known as acetylsalicylic acid (acetylsalicylic acid), is a salicylic acid drug commonly used as a painkiller, antipyretic and anti-inflammatory drug. There is growing evidence that aspirin has a preventive effect on certain cancers, especially gastrointestinal cancers, and that taking aspirin every day can reduce the risk of colon cancer, and in vitro experiments have also shown that aspirin inhibits the growth of a variety of cancer cells and induces apoptosis.
Study: NCT00425386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Dose Level 0 = 50 mg/day, continuous daily; 0.5= 75 mg/day, continuous daily;~1. 100 mg/day, continuous daily; 1.5= 125 mg/day, continuous daily;~2. 150 mg/day, continuous daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Will be administered at 50 mg daily, 4 weeks on, 2 weeks off

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Paraffin block (or unstained slides) of the primary tumor and/or metastatic lesions (as available) and a plasma sample for future correlative studies will be collected. A paraffin block (or at least 10 unstained slides, each of 10 micromillimeter thickness) from the original paraffin-embedded biopsy material taken at the diagnosis will be stored at 4 degrees Celsius.
Study: NCT01664780

Intervention type: DEVICE
Intervention: ARFI imaging
Study: NCT04565678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitapivat tablets
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitapivat tablets
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitapivat tablets
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitapivat tablets
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitapivat coated granules
Description: Oral coated granules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitapivat coated granules
Description: Oral coated granules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitapivat coated granules
Description: Oral coated granules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitapivat coated granules
Description: Oral coated granules
Study: NCT04041882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATATE
Description: Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-DOTATATE. Tracer doses of 68Ga-DOTATATE will be used to image lesions of NET PET/CT scan.
Study: NCT05595044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: ASD children with vitamin D insufficiency and deficiency will receive vitamin D with dose 300 IU/KG/ day not exceed 5000IU/day for 6 weeks then revaluate serum level of vitamin D if they reach normal level of vitamin D they will receive vitamin D 1000IU/ day till the end of 4 months.

Intervention type: OTHER
Group type: OTHER
Intervention: Habilitation
Description: Habilitation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Habilitation
Description: Habilitation
Study: NCT02615444

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-glucan enriched oatcake
Description: 5 oatcakes enriched with oat beta-glucan will be consumed daily for six weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Isocaloric control
Description: 6.5 wheat based control snacks without beta-glucan will be consumed daily for six weeks
Study: NCT00767897

Intervention type: DRUG
Intervention: Human Papillomavirus Vaccine
Description: The HPV vaccination will be administered by intramuscular injection in three separate 0.5mL doses. The recommended schedule is a 3-dose series with dose #2 and #3 administered 2 and 6 months after dose #1, respectively. The minimum interval between dose #1 and #2 of the vaccine is 4 weeks. The minimum recommended interval between dose #2 and #3 of the vaccine is 12 weeks.

Intervention type: DRUG
Intervention: Human Papillomavirus Vaccine
Description: The HPV vaccination will be administered by intramuscular injection in three separate 0.5mL doses. The recommended schedule is a 3-dose series with dose #2 and #3 administered 2 and 6 months after dose #1, respectively. The minimum interval between dose #1 and #2 of the vaccine is 4 weeks. The minimum recommended interval between dose #2 and #3 of the vaccine is 12 weeks.

Intervention type: DRUG
Intervention: Human Papillomavirus Vaccine
Description: The HPV vaccination will be administered by intramuscular injection in three separate 0.5mL doses. The recommended schedule is a 3-dose series with dose #2 and #3 administered 2 and 6 months after dose #1, respectively. The minimum interval between dose #1 and #2 of the vaccine is 4 weeks. The minimum recommended interval between dose #2 and #3 of the vaccine is 12 weeks.

Intervention type: DRUG
Intervention: Human Papillomavirus Vaccine
Description: The HPV vaccination will be administered by intramuscular injection in three separate 0.5mL doses. The recommended schedule is a 3-dose series with dose #2 and #3 administered 2 and 6 months after dose #1, respectively. The minimum interval between dose #1 and #2 of the vaccine is 4 weeks. The minimum recommended interval between dose #2 and #3 of the vaccine is 12 weeks.
Study: NCT03920670

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TetraGraph (TG)
Description: TetraGraph device is a neuromuscular transmission monitor capable of estimating the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to percutaneous electrical neurostimulation. Following simultaneous ulnar nerve stimulation on each arm, the response of the adductor pollicis will be measured.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TetraGraph (TG)
Description: TetraGraph device is a neuromuscular transmission monitor capable of estimating the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to percutaneous electrical neurostimulation. Following simultaneous ulnar nerve stimulation on each arm, the response of the adductor pollicis will be measured.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ToFscan (TS)
Description: ToFscan is a nerve stimulator module used for the measurement of neuromuscular transmission via accelerometry. ToFscan was developed by Drager Technologies, Canada, and it uses a three-dimensional piezoelectric sensor that attaches to the thumb via a hand adapter to measure acceleration in multiple planes (Murphy et al, 2018). Following simultaneous ulnar nerve stimulation on each arm, the response of the adductor pollicis will be measured.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ToFscan (TS)
Description: ToFscan is a nerve stimulator module used for the measurement of neuromuscular transmission via accelerometry. ToFscan was developed by Drager Technologies, Canada, and it uses a three-dimensional piezoelectric sensor that attaches to the thumb via a hand adapter to measure acceleration in multiple planes (Murphy et al, 2018). Following simultaneous ulnar nerve stimulation on each arm, the response of the adductor pollicis will be measured.
Study: NCT02772432

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Response Resiliency Training for Parents of SPLD

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Response Resiliency Training for Parents of SPLD
Study: NCT00476879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin and pegvisomant
Description: Somatropin are given intravenous, 0.5mg pegvisomant are given subcutaneous, 15 mg NaCl are given subcutaneous, 2 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin and pegvisomant
Description: Somatropin are given intravenous, 0.5mg pegvisomant are given subcutaneous, 15 mg NaCl are given subcutaneous, 2 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin and pegvisomant
Description: Somatropin are given intravenous, 0.5mg pegvisomant are given subcutaneous, 15 mg NaCl are given subcutaneous, 2 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin and pegvisomant
Description: Somatropin are given intravenous, 0.5mg pegvisomant are given subcutaneous, 15 mg NaCl are given subcutaneous, 2 ml
Study: NCT01986543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: drug administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: drug administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: drug administration
Study: NCT02428257

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: continuous spinal anesthesia
Description: Spinal puncture performed with a 19-gauge Tuohy needle at the L4-L5 or L3-L4 interspace using a midline approach. 3 cm of a 22-gauge catheter introduced through the needle, directed to the fractured side.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: continuous spinal anesthesia
Description: Spinal puncture performed with a 19-gauge Tuohy needle at the L4-L5 or L3-L4 interspace using a midline approach. 3 cm of a 22-gauge catheter introduced through the needle, directed to the fractured side.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hypobaric bupivacaine
Description: hypobaric bupivacaine was prepared diluting each 1 ml of 0.5% isobaric bupivacaine with 1 ml of sterile water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isobaric bupivacaine
Description: 0.5% isobaric bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ephedrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ephedrine
Study: NCT01238458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]AV-45 PET amyloid binding imaging
Description: This study will recruit a total of 150 evaluable subjects (30 cognitively normal volunteers, and 60 MCI, and 60 AD, respectively) Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.~Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events.
Study: NCT00278993

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E7389
Description: Intravenous 1.4 mg/m2 on a 3-week course.
Study: NCT03502993

Intervention type: DIAGNOSTIC_TEST
Intervention: Validation of biomarker

Intervention type: DIAGNOSTIC_TEST
Intervention: Validation of biomarker
Study: NCT04001023

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imaging with 18F-EF5 PET/CT
Description: Both 18F-FDG PET/CT and 18F-EF5 PET/CT imaging are performed in 1) preoperative work-up to clarify the disease distribution, 2) before IDS to evaluate treatment response to NACT (IDS arm); targeted samples from hypoxic and non-hypoxic tumors are collected during surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imaging with 18F-EF5 PET/CT
Description: Both 18F-FDG PET/CT and 18F-EF5 PET/CT imaging are performed in 1) preoperative work-up to clarify the disease distribution, 2) before IDS to evaluate treatment response to NACT (IDS arm); targeted samples from hypoxic and non-hypoxic tumors are collected during surgery
Study: NCT02554097

Intervention type: PROCEDURE
Intervention: endoscopic sphincterotomy
Description: Sphincterotomy (EST) is performed to remove the common bile duct stone.

Intervention type: PROCEDURE
Intervention: laparoscopic common bile duct exploration
Description: Transductal exploration was carried out to remove the common bile duct stone. Primary closure or a T tube drainage was performed according to the results of transductal surgery.

Intervention type: PROCEDURE
Intervention: laparoscopic transcystic common bile duct exploration
Description: A wide local dissection of Calot's triangle is performed and a 2.8mm, 3-mm or 5-mm flexible choledochoscope according to the diameter of the cystic duct is inserted through the cystic duct into the common bile duct. After the common bile duct stone is removed, the cystic duct was ligated with Hem-o-lok.

Intervention type: PROCEDURE
Intervention: laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy is performed to remove the gallbladder.

Intervention type: PROCEDURE
Intervention: laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy is performed to remove the gallbladder.

Intervention type: PROCEDURE
Intervention: laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy is performed to remove the gallbladder.
Study: NCT02586168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcabene 900 mg
Description: Gemcabene 900 mg once daily (QD)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04485312

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: preventive protocol
Description: preventive protocol

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: chlorhexidine added to the preventive protocol
Description: chlorhexidine varnish added to the preventive protocol
Study: NCT01394146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Research diet
Description: Participants will be provided specially prepared meals to eat at home for two weeks. During the first week, participants will eat foods that do not have any phosphorus-based food additives in them (this is called the control diet). During the second week, participants will eat foods that all have phosphorus-based food additives in them (called the intervention diet).
Study: NCT02706808

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 'resistance starch for CKD
Description: Intervention period (6 weeks): Group A - patients will receive 6 cookies/day containing resistant starch (18g/day); Group B - patients will receive 6 cookies/day containing placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intervention period (6 weeks): Group B - patients will receive 6 cookies/day containing resistant starch (18g/day); Group A - patients will receive 6 cookies/day containing placebo
Study: NCT00941265

Intervention type: DRUG
Group type: OTHER
Intervention: levodopa and benserazide
Description: Daily Monday to Friday CAT with Daily Monday to Friday levodopa 100 mg with benserazide 25 mg , in the morning 1 h after breakfast, during 2 weeks .

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: Daily CAT Monday to Friday with daily placebo Monday to Friday , in the morning 1 h after breakfast, taken 5 out of 7 days during the 2 weeks of one of the two treatment periods.
Study: NCT00865072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin HCl 750 mg Extender Release tablets, single dose
Description: A: Experimental Subjects received Purepac formulated products under fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLUCOPHAGE® XR 750 mg tablets, single dose
Description: B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
Study: NCT01634555

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab (IMC-1121B)
Description: Ramucirumab (IMC-1121B) 8 milligrams per kilogram (mg/kg), administered as an intravenous (IV) infusion on Day 1 of each 2-week cycle (except Cycle 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 milligrams per square meter (mg/m²) administered IV on Day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic acid
Description: 400 mg/m² administered IV on Day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 400 mg/m² bolus over 2 to 4 minutes administered IV on Day 1 of each cycle, followed by 2400 mg/m² administered IV over 46 to 48 hours on Days 1 and 2 of each cycle